Can a targeted drug combo outsmart advanced head and neck cancer?

This phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to the standard immunotherapy pembrolizumab can better control recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls adults whose tumors express a specific protein (c-Met) and who have not yet received systemic treatment for advanced disease. Participants are randomly assigned to receive either the new combination or standard chemotherapy plus pembrolizumab. The goal is to see if the new combo improves tumor response and delays progression, while also assessing safety.